{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:22:52Z","timestamp":1791217372954,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research Establishment Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Canadian Foundation for Innovation Funding"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.jns.2012.12.023","type":"journal-article","created":{"date-parts":[[2013,1,11]],"date-time":"2013-01-11T15:01:20Z","timestamp":1357916480000},"page":"142-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy"],"prefix":"10.1016","volume":"325","author":[{"given":"Henry A.J.","family":"Stringer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurmeet K.","family":"Sohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne C.F.","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.jns.2012.12.023_bb0005","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jns.2012.12.023_bb0010","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jns.2012.12.023_bb0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3949\/ccjm.78a.10073","article-title":"Statin myopathy: a common dilemma not reflected in clinical trials","volume":"78","author":"Fernandez","year":"2011","journal-title":"Cleve Clin J Med"},{"issue":"21","key":"10.1016\/j.jns.2012.12.023_bb0020","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"issue":"9601","key":"10.1016\/j.jns.2012.12.023_bb0025","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"issue":"2A","key":"10.1016\/j.jns.2012.12.023_bb0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0002-9343(97)00467-1","article-title":"Compliance with treatment regimens in chronic asymptomatic diseases","volume":"102","author":"Miller","year":"1997","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.jns.2012.12.023_bb0035","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0025-6196(11)60897-5","article-title":"Toward \u201cpain-free\u201d statin prescribing: clinical algorithm for diagnosis and management of myalgia","volume":"83","author":"Jacobson","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.jns.2012.12.023_bb0040","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMc0908215","article-title":"Neuromuscular symptoms and elevated creatine kinase after statin withdrawal","volume":"362","author":"Echaniz-Laguna","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jns.2012.12.023_bb0045","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"issue":"1\u20132","key":"10.1016\/j.jns.2012.12.023_bb0050","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/cmaj.081785","article-title":"Association between statin-associated myopathy and skeletal muscle damage","volume":"181","author":"Mohaupt","year":"2009","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.jns.2012.12.023_bb0055","first-page":"85","article-title":"Mitochondrial alterations in muscle biopsies of patients on statin therapy","volume":"36","author":"Gambelli","year":"2004","journal-title":"J Submicrosc Cytol Pathol"},{"issue":"1","key":"10.1016\/j.jns.2012.12.023_bb0060","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0002-9343(93)90129-D","article-title":"Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome","volume":"94","author":"Chariot","year":"1993","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.jns.2012.12.023_bb0065","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/jcp.2004.015958","article-title":"Statin precipitated lactic acidosis?","volume":"57","author":"Neale","year":"2004","journal-title":"J Clin Pathol"},{"issue":"4","key":"10.1016\/j.jns.2012.12.023_bb0070","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000101287","article-title":"Statins provoking MELAS syndrome. A case report","volume":"57","author":"Thomas","year":"2007","journal-title":"Eur Neurol"},{"issue":"4","key":"10.1016\/j.jns.2012.12.023_bb0075","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1445-5994.1995.tb01912.x","article-title":"Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors\u2014simvastatin and pravastatin","volume":"25","author":"England","year":"1995","journal-title":"Aust N Z J Med"},{"issue":"4","key":"10.1016\/j.jns.2012.12.023_bb0080","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/art.22100","article-title":"In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects","volume":"55","author":"Guis","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.jns.2012.12.023_bb0085","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/01.SMJ.0000061501.81880.83","article-title":"Statins unmasking a mitochondrial myopathy: a case report and proposed mechanism of disease","volume":"96","author":"Diaczok","year":"2003","journal-title":"South Med J"},{"issue":"6","key":"10.1016\/j.jns.2012.12.023_bb0090","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"10.1016\/j.jns.2012.12.023_bb0095","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMp1106689","article-title":"Weighing the benefits of high-dose simvastatin against the risk of myopathy","volume":"365","author":"Egan","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jns.2012.12.023_bb0100","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jns.2012.12.023_bb0105","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clpt.2006.06.010","article-title":"SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin","volume":"80","author":"Niemi","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jns.2012.12.023_bb0110","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.jns.2012.12.023_bb0115","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid","volume":"16","author":"Pasanen","year":"2006","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"10.1016\/j.jns.2012.12.023_bb0120","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/CIRCRESAHA.109.203596","article-title":"Human skeletal muscle drug transporters determine local exposure and toxicity of statins","volume":"106","author":"Knauer","year":"2010","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.jns.2012.12.023_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/tpj.2009.54","article-title":"The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy","volume":"10","author":"Romaine","year":"2010","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"10.1016\/j.jns.2012.12.023_bb0130","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.clpt.6100124","article-title":"Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin","volume":"81","author":"Schick","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jns.2012.12.023_bb0135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/gerona\/62.3.235","article-title":"Accumulation of mitochondrial DNA deletion mutations in aged muscle fibers: evidence for a causal role in muscle fiber loss","volume":"62","author":"Herbst","year":"2007","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"3","key":"10.1016\/j.jns.2012.12.023_bb0140","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1086\/507132","article-title":"Mitochondrial DNA-deletion mutations accumulate intracellularly to detrimental levels in aged human skeletal muscle fibers","volume":"79","author":"Bua","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"8","key":"10.1016\/j.jns.2012.12.023_bb0145","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.bcp.2011.01.022","article-title":"Statin or fibrate chronic treatment modifies the proteomic profile of rat skeletal muscle","volume":"81","author":"Camerino","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jns.2012.12.023_bb0150","article-title":"Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a \u2018mitohormesis\u2019 mechanism involving reactive oxygen species and PGC-1","author":"Bouitbir","year":"2011","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jns.2012.12.023_bb0155","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1567-1364.2006.00194.x","article-title":"Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata","volume":"7","author":"Westermeyer","year":"2007","journal-title":"FEMS Yeast Res"},{"issue":"Pt 6","key":"10.1016\/j.jns.2012.12.023_bb0160","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1042\/BST0351529","article-title":"Biological consequences of statins in Candida species and possible implications for human health","volume":"35","author":"Wikhe","year":"2007","journal-title":"Biochem Soc Trans"},{"issue":"11","key":"10.1016\/j.jns.2012.12.023_bb0165","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa012035","article-title":"Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients","volume":"346","author":"Cote","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jns.2012.12.023_bb0170","first-page":"159","article-title":"Measuring oxidative mtDNA damage and repair using quantitative PCR","volume":"197","author":"Santos","year":"2002","journal-title":"Methods Mol Biol"},{"issue":"6","key":"10.1016\/j.jns.2012.12.023_bb0175","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/QAD.0b013e32835142eb","article-title":"Blood mitochondrial DNA mutations in HIV-Infected women and their infants exposed to highly active antiretroviral therapy during pregnancy","volume":"26","author":"Jitratkosol","year":"2012","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.jns.2012.12.023_bb0180","first-page":"169","article-title":"Could mitochondrial DNA quantitation be a surrogate marker for drug mitochondrial toxicity?","volume":"6","author":"de Mendoza","year":"2004","journal-title":"AIDS Rev"},{"issue":"1","key":"10.1016\/j.jns.2012.12.023_bb0185","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial","volume":"78","author":"Paiva","year":"2005","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X1200648X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X1200648X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:42:31Z","timestamp":1758382951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X1200648X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":37,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0022510X1200648X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2012.12.023","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2012.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}